OM:GENI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Generic Sweden AB provides consulting and telecommunication services in Sweden. More Details


Snowflake Analysis

Flawless balance sheet with solid track record.

Share Price & News

How has Generic Sweden's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GENI is more volatile than 90% of Swedish stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: GENI's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Swedish stocks.


Market Performance


7 Day Return

10.2%

GENI

2.4%

SE IT

0.6%

SE Market


1 Year Return

173.0%

GENI

27.6%

SE IT

17.1%

SE Market

Return vs Industry: GENI exceeded the Swedish IT industry which returned 27.6% over the past year.

Return vs Market: GENI exceeded the Swedish Market which returned 17.1% over the past year.


Shareholder returns

GENIIndustryMarket
7 Day10.2%2.4%0.6%
30 Day6.0%4.7%8.0%
90 Day29.8%11.7%8.3%
1 Year183.4%173.0%29.2%27.6%18.9%17.1%
3 Year1,246.2%955.6%54.6%47.6%41.5%26.2%
5 Year1,424.5%969.8%137.2%115.6%63.2%31.7%

Long-Term Price Volatility Vs. Market

How volatile is Generic Sweden's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Generic Sweden undervalued compared to its fair value and its price relative to the market?

59.35x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: GENI (SEK47.5) is trading above our estimate of fair value (SEK23.56)

Significantly Below Fair Value: GENI is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: GENI is poor value based on its PE Ratio (59.4x) compared to the SE IT industry average (26.4x).

PE vs Market: GENI is poor value based on its PE Ratio (59.4x) compared to the Swedish market (22.8x).


Price to Earnings Growth Ratio

PEG Ratio: GENI is poor value based on its PEG Ratio (3.4x)


Price to Book Ratio

PB vs Industry: GENI is overvalued based on its PB Ratio (36.4x) compared to the SE IT industry average (3.8x).


Next Steps

Future Growth

How is Generic Sweden forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

17.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GENI's forecast earnings growth (17.7% per year) is above the savings rate (0.5%).

Earnings vs Market: GENI's earnings (17.7% per year) are forecast to grow faster than the Swedish market (11.6% per year).

High Growth Earnings: GENI's earnings are forecast to grow, but not significantly.

Revenue vs Market: GENI's revenue (13% per year) is forecast to grow faster than the Swedish market (3.4% per year).

High Growth Revenue: GENI's revenue (13% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GENI's Return on Equity is forecast to be very high in 3 years time (45.4%).


Next Steps

Past Performance

How has Generic Sweden performed over the past 5 years?

20.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GENI has a high level of non-cash earnings.

Growing Profit Margin: GENI's current net profit margins (13.1%) are higher than last year (11.6%).


Past Earnings Growth Analysis

Earnings Trend: GENI's earnings have grown significantly by 20.2% per year over the past 5 years.

Accelerating Growth: GENI's earnings growth over the past year (32.3%) exceeds its 5-year average (20.2% per year).

Earnings vs Industry: GENI earnings growth over the past year (32.3%) exceeded the IT industry 7.7%.


Return on Equity

High ROE: GENI's Return on Equity (61.4%) is considered outstanding.


Next Steps

Financial Health

How is Generic Sweden's financial position?


Financial Position Analysis

Short Term Liabilities: GENI's short term assets (SEK30.6M) exceed its short term liabilities (SEK12.3M).

Long Term Liabilities: GENI's short term assets (SEK30.6M) exceed its long term liabilities (SEK6.1M).


Debt to Equity History and Analysis

Debt Level: GENI is debt free.

Reducing Debt: GENI has not had any debt for past 5 years.

Debt Coverage: GENI has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: GENI has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Generic Sweden current dividend yield, its reliability and sustainability?

0.63%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: GENI's dividend (0.63%) isn’t notable compared to the bottom 25% of dividend payers in the Swedish market (1.19%).

High Dividend: GENI's dividend (0.63%) is low compared to the top 25% of dividend payers in the Swedish market (3.76%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, GENI has been paying a dividend for less than 10 years.

Growing Dividend: GENI has only been paying a dividend for 5 years, and since then payments have not increased.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (37.5%), GENI's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: GENI's dividends in 3 years are forecast to be covered by earnings (84.1% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

11.0yrs

Average board tenure


CEO

Jonas Jegerborn (48 yo)

no data

Tenure

kr2,316,000

Compensation

Mr. Jonas Jegerborn serves as a Chief Executive Officer and President at Generic Sweden AB.


CEO Compensation Analysis

Compensation vs Market: Jonas's total compensation ($USD271.60K) is about average for companies of similar size in the Swedish market ($USD235.13K).

Compensation vs Earnings: Insufficient data to compare Jonas's compensation with company performance.


Board Members

NamePositionTenureCompensationOwnership
Fredrik Svedberg
Owner & Member of the board11yrskr75.00kno data
Kent-Åke Jönsson
Independent Director11.5yrskr75.00kno data
Hans Krantz
Chairman of the Board11yrskr150.00kno data
Stefan Widén
Independent Director6.5yrskr75.00kno data
Niclas Granholm
Director2.5yrskr75.00k0.016%
SEK 87.0k

11.0yrs

Average Tenure

61yo

Average Age

Experienced Board: GENI's board of directors are seasoned and experienced ( 11 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Generic Sweden AB's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Generic Sweden AB
  • Ticker: GENI
  • Exchange: OM
  • Founded: 1993
  • Industry: IT Consulting and Other Services
  • Sector: Software
  • Market Cap: kr534.703m
  • Shares outstanding: 12.29m
  • Website: https://www.generic.se

Number of Employees


Location

  • Generic Sweden AB
  • Hangovagen 18
  • Stockholm
  • Stockholm County
  • 115 41
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GENIOM (OMX Nordic Exchange Stockholm)YesCommon SharesSESEKJan 2007

Biography

Generic Sweden AB provides consulting and telecommunication services in Sweden. The company’s Consultancy division offers high-quality services to clients within the defense and civil security sector, as w...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/27 18:40
End of Day Share Price2020/11/27 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.